BACKGROUND: Central nervous system (CNS) complications of Langerhans cell histiocytosis (LCH) include mass lesions and a neurodegenerative (ND) syndrome with ataxia, dysarthria, dysmetria, learning and behavior difficulties and/or characteristic changes on brain MRIs. Hydrocephalus has rarely been reported in LCH. LCH lesions of the orbit, mastoid and temporal bones ("CNS-Risk" lesions) and diabetes insipidus predispose patients to ND-CNS-LCH. Treatment options have been limited and only a case series using trans-retinoic acid (ATRA) and intravenous immunoglobulin (IVIG) have been published. METHODS: We have used cytosine arabinoside (ARA-C) with or without vincristine to treat eight patients with ND-CNS LCH. PATIENTS: Seven male children and one young adult male with clinical and radiologic ND-CNS-LCH were treated with a regimen of vincristine 1.5 mg/m(2) on day 1 and ARA-C 100 mg/m(2) daily for 5 days or ARA-C alone monthly for 4-19 months. Seven patients were evaluated with an ataxia rating scale (ARS) and all with serial MRIs of the brain. RESULTS: Five of seven patients had decreases in their ARS scores and/or decreased T2 hyperintense lesions on MRI images. Grade 2 neutropenia was the most frequent adverse event. Vincristine-associated neuropathy occurred in two patients. Hydrocephalus caused symptoms and signs that confounded the diagnosis and management of ND-CNS-LCH in all four patients affected with both. CONCLUSIONS: Subtle changes in neurologic function may be complicated by hydrocephalus. Vcr/ARA-C or ARA-C were an effective therapies for some ND-CNS LCH patients. A clinical trial using this and possibly other modalities such as IVIG or ATRA should be done. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND: Central nervous system (CNS) complications of Langerhans cell histiocytosis (LCH) include mass lesions and a neurodegenerative (ND) syndrome with ataxia, dysarthria, dysmetria, learning and behavior difficulties and/or characteristic changes on brain MRIs. Hydrocephalus has rarely been reported in LCH. LCH lesions of the orbit, mastoid and temporal bones ("CNS-Risk" lesions) and diabetes insipidus predispose patients to ND-CNS-LCH. Treatment options have been limited and only a case series using trans-retinoic acid (ATRA) and intravenous immunoglobulin (IVIG) have been published. METHODS: We have used cytosine arabinoside (ARA-C) with or without vincristine to treat eight patients with ND-CNS LCH. PATIENTS: Seven male children and one young adult male with clinical and radiologic ND-CNS-LCH were treated with a regimen of vincristine 1.5 mg/m(2) on day 1 and ARA-C 100 mg/m(2) daily for 5 days or ARA-C alone monthly for 4-19 months. Seven patients were evaluated with an ataxia rating scale (ARS) and all with serial MRIs of the brain. RESULTS: Five of seven patients had decreases in their ARS scores and/or decreased T2 hyperintense lesions on MRI images. Grade 2 neutropenia was the most frequent adverse event. Vincristine-associated neuropathy occurred in two patients. Hydrocephalus caused symptoms and signs that confounded the diagnosis and management of ND-CNS-LCH in all four patients affected with both. CONCLUSIONS: Subtle changes in neurologic function may be complicated by hydrocephalus. Vcr/ARA-C or ARA-C were an effective therapies for some ND-CNS LCHpatients. A clinical trial using this and possibly other modalities such as IVIG or ATRA should be done. Copyright 2009 Wiley-Liss, Inc.
Authors: Antje Wick; Wolfgang Wick; Johannes Hirrlinger; Ellen Gerhardt; Ralf Dringen; Johannes Dichgans; Michael Weller; Jörg B Schulz Journal: J Neurochem Date: 2004-12 Impact factor: 5.372
Authors: Girish Dhall; Jonathan L Finlay; Ira J Dunkel; Lawrence J Ettinger; Stewart J Kellie; Jeffrey C Allen; R Maarten Egeler; Robert J Arceci Journal: Pediatr Blood Cancer Date: 2008-01 Impact factor: 3.167
Authors: Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen Journal: Nat Rev Dis Primers Date: 2021-10-07 Impact factor: 65.038
Authors: Kenneth L McClain; Jennifer Picarsic; Rikhia Chakraborty; Daniel Zinn; Howard Lin; Harshal Abhyankar; Brooks Scull; Albert Shih; Karen Phaik Har Lim; Olive Eckstein; Joseph Lubega; Tricia L Peters; Walter Olea; Thomas Burke; Nabil Ahmed; M John Hicks; Brandon Tran; Jeremy Jones; Robert Dauser; Michael Jeng; Robert Baiocchi; Deborah Schiff; Stanton Goldman; Kenneth M Heym; Harry Wilson; Benjamin Carcamo; Ashish Kumar; Carlos Rodriguez-Galindo; Nicholas S Whipple; Patrick Campbell; Geoffrey Murdoch; Julia Kofler; Simon Heales; Marian Malone; Randy Woltjer; Joseph F Quinn; Paul Orchard; Michael C Kruer; Ronald Jaffe; Markus G Manz; Sergio A Lira; D Williams Parsons; Miriam Merad; Tsz-Kwong Man; Carl E Allen Journal: Cancer Date: 2018-04-06 Impact factor: 6.860
Authors: Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain Journal: Orphanet J Rare Dis Date: 2013-05-14 Impact factor: 4.123
Authors: Amel Sengal; Jessica Velazquez; Meryl Hahne; Thomas M Burke; Harshal Abhyankar; Robert Reyes; Walter Olea; Brooks Scull; Olive S Eckstein; Camille Bigenwald; Catherine M Bollard; Wendong Yu; Miriam Merad; Kenneth L McClain; Carl E Allen; Rikhia Chakraborty Journal: Blood Date: 2021-04-01 Impact factor: 25.476